New Kinase Inhibitors That Are Selectively Cytotoxic for Tumor Cells

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Developing targeted cancer therapies requires identifying compounds with selective cytotoxicity against tumor cells.
• Phenotypic screening in cocultures offers a method to discover such selective agents.

Purpose of the Study:

• To identify novel compounds with selective activity against tumor cells using phenotypic screening.
• To characterize the mechanism of action of identified compounds as kinase inhibitors.

Main Methods:

• Phenotypic screening of compounds in cocultures of tumor and non-tumor cell lines (MCF7/MCF10A).
• Structural analysis of active compounds to identify characteristic motifs.
• Assay of kinase inhibition activity for identified compounds.
• Determination of selectivity index across different cell lines (PC3 vs. VA13).

Main Results:

• Compound STOCK7S-36520 demonstrated selective cytotoxicity in a breast tumor cell coculture.
• STOCK7S-36520 and its derivative STOCK7S-47016 were identified as novel multikinase inhibitors.
• STOCK7S-47016 achieved 84% inhibition against GCK kinase.
• STOCK7S-36520 exhibited a 29-fold selectivity index against prostate tumor cells (PC3) compared to fibroblasts (VA13).

Conclusions:

• Novel multikinase inhibitors, STOCK7S-36520 and STOCK7S-47016, have been discovered.
• These compounds display selective cytotoxicity against tumor cells, indicating potential therapeutic applications.
• The identified inhibitors target specific kinases, offering a basis for further drug development in oncology.